International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 609-610 , June 2010

In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae

References 

  1. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol. 2009;30:972–976
  2. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35:240–243
  3. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34:506–515
  4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
  5. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother. 2009;50:3098–3101
  6. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time–kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40:1914–1918
  7. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In:  Lorian V editors. Antibiotics in laboratory medicine. 4th ed.. Baltimore, MD: Williams & Wilkins; 1996;p. 330–396

PII: S0924-8579(10)00066-X

doi: 10.1016/j.ijantimicag.2010.01.021

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 609-610 , June 2010

Article Tools